News

Terumo Health Outcomes Announces Distribution Agreement for Caretaker Medical’s VitalStream® Non-Invasive Hemodynamic Monitoring

Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), today announced a new U.S. distribution agreement with Caretaker Medical to offer Caretaker Medical’s VitalStream wearable hemodynamic monitoring platform to hospitals nationwide. This agreement is yet another step in THO’s continued effort to bring forward-looking technologies to cardiovascular care teams seeking smarter, more efficient ways to monitor patient status and act sooner in the care process.

“We’re excited to partner with Terumo Health Outcomes to deliver impactful solutions for the early identification and improved treatment of shock and heart failure,” said Jeff Pompeo, CEO, Caretaker Medical. “Our VitalStream platform’s capability to deliver real-time, beat-by-beat physiological data – including continuous blood pressure and hemodynamics through a comfortable, non-invasive wearable – is central to this.”

Together, THO and Caretaker Medical are enabling clinicians to detect changes sooner and respond with confidence by eliminating invasive lines and bulky wires, especially in high-acuity cardiovascular settings like cath labs and cardiac step-down units – where timely and accurate intervention for these conditions is critical.

“Clinicians need reliable, non-invasive options for continuous monitoring, particularly in settings where invasive lines aren’t feasible or desired,” said Ghada Farah, President of Terumo Interventional Systems, Cardiac and Vascular Company at Terumo. “Caretaker’s VitalStream technology fits our mission of delivering tools that support earlier intervention and more informed decisions, while also helping hospitals improve clinical workflows and patient safety.”

THO is a division of TIS, which offers a portfolio of high-quality interventional devices that complement the predictive insights offered by THO’s ePRISM platform. While ePRISM assists clinicians in identifying patient risk and optimizing treatment strategies, the advanced tools from TIS support procedural efficiency, contributing to improved patient outcomes. This combination assists clinicians to make more informed decisions, facilitating smoother procedures and potentially reducing hospital costs and recovery times. Learn more at www.terumohealthoutcomes.com.

 

Read more here.

Recent News

04/08/2026

Likarda and The Tiny Cargo Company Announce Strategic Partnership to Advance Next-Generation Delivery of Biologics, Peptides and Small Molecules

Likarda, Inc., a leader in hydrogel-based drug delivery technologies, today announced a strategic partnership with Tiny Cargo, an innovator in extracellular vesicle (EV) delivery systems. The collaboration will focus on advancing the delivery of biologics and small molecules by integrating Likarda’s Core-Shell Spherification® (CSS®) platform with Tiny Cargo’s vesicle-based technologies. The partnership is designed to

04/08/2026

ReAlta Life Sciences Closes Oversubscribed $40 Million Financing Round to Advance Pegtarazimod Phase 2 Program in Hypoxic Ischemic Encephalopathy (HIE)

ReAlta Life Sciences Inc. (“ReAlta” or the “Company”), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to potentially revolutionize the treatment of inflammatory disorders, today announced the closing of an oversubscribed $40 million financing. This brings the total capital raised to date to more than $150 million.

04/02/2026

ATCC Receives New CDC Award to Help Fast-track Diagnostic Tests for Future Disease Outbreaks

TCC has been selected by the Centers for Disease Control and Prevention (CDC) Office of Readiness and Response (ORR) for a new five-year contract to support rapid test development during public health emergencies. The award, valued at up to $148 million (IDIQ contract 75D301-25-R-73207), will help ensure that diagnostic tools can be quickly created, validated,